Pomalidomide-amido-C1-Br
Code | Size | Price |
---|
TAR-T18552-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T18552-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Pomalidomide-amido-C1-Br is a synthesized conjugate consisting of the Pomalidomide-based cereblon ligand and a linker, functioning as an E3 ligase ligand-linker. This compound serves as a tool for designing a B-Raf PROTAC degrader, specifically PROTAC B-Raf degrader 1, which exhibits anti-cancer activity[1].
CAS:
2351106-38-0
Molecular Weight:
394.18
Purity:
0.98
SMILES:
O=C(NC1=CC=CC=2C(=O)N(C(=O)C12)C3C(=O)NC(=O)CC3)CBr
References
Chen H, et al. Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation. Bioorg Chem. 2019 Jun;87:191-199.